Castle Biosciences unveiled AdvanceAD-Tx, its pipeline atopic dermatitis (AD) gene expression profile (GEP) test at the 2025 Fall Clinical Dermatology Conference in Las Vegas, NV.
The 487-gene expression profile test guides systemic therapy selection in AD, eliminating some of the trial and error involved in choosing systemic therapy for patients and improving care. The pipeline AD test can classify a patient’s underlying disease biology as having a T helper 2 (Th2) Molecular Profile or a Janus Kinase Inhibitor (JAKi) Responder Profile and guide treatment decisions accordingly. Derek Maetzold, President and Chief Executive Officer of Castle Biosciences, reviews the test’s power and promise and shares some details about its planned rollout.
